$7.36−0.20 (−2.65%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Olema Oncology (OLMA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+120.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼25.5%
−162.5
FY21→FY25CAGR —
Free cash flow ($M)▼40.4%
−146.7
FY21→FY25CAGR —
Diluted EPS▲15.0%
−1.87
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+120.1%
39.5mn → 87.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$0.0K
−100.0% YoY in FY25.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 217,835.0 | 157,697.0 | 124,517.0 | 86,140.0 | 82,274.0 | 51,100.0 | ▲26.6% | +32.5% |
Selling, general & admin | 34,939.0 | 21,001.0 | 17,741.0 | 18,821.0 | 24,714.0 | 20,391.0 | ▲18.4% | +0.7% |
Total operating expenses | 252,774.0 | 178,698.0 | 142,258.0 | 104,961.0 | 106,988.0 | 71,491.0 | ▲25.6% | +25.7% |
Operating incomefeeds ROC rank | −252,774.0 | −178,698.0 | −142,258.0 | −104,961.0 | −106,988.0 | −71,491.0 | ▼25.6% | — |
Other income, net | 16,825.0 | 16,247.0 | 12,784.0 | 8,306.0 | 2,201.0 | 395.0 | — | — |
Pretax income | −235,949.0 | −162,451.0 | −129,474.0 | −96,655.0 | −104,787.0 | −71,096.0 | ▼25.5% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −235,949.0 | −162,451.0 | −129,474.0 | −96,655.0 | −104,787.0 | −71,096.0 | ▼25.5% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −2.37 | −1.87 | −2.20 | −2.14 | −2.62 | −1.80 | ▲15.0% | — |
Diluted shares (mn) | 101.09 | 87.01 | 58.74 | 45.25 | 40.00 | 39.52 | ▲48.1% | +21.8% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-16 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

